PriceTargets.com logo

Eidos Therapeutics - EIDX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$122.21 As of 01/26/2021 01:00 AM ET
+0 (0.00%)
Get New Eidos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EIDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EIDX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Eidos Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $122.21.

This chart shows the closing price for EIDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Eidos Therapeutics. This rating has held steady since December 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/30/2020Smith Barney CitigroupReiterated RatingBuyN/A
11/18/2020BTIG ResearchDowngradeBuy ➝ NeutralLow
10/7/2020CitigroupDowngradeBuy ➝ Neutral$80.00 ➝ $73.26Medium
10/6/2020BMO Capital MarketsDowngradeOutperform ➝ Market PerformMedium
10/5/2020SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
10/5/2020Piper SandlerDowngradeOverweight ➝ NeutralHigh
9/22/2020GuggenheimDowngradeBuy ➝ NeutralHigh
9/8/2020CitigroupInitiated CoverageBuy$80.00High
5/14/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$58.00 ➝ $50.00Medium
5/11/2020BarclaysLower TargetUnderweight$45.00 ➝ $34.00High
5/11/2020SVB LeerinkLower TargetOutperform$62.00 ➝ $59.00High
4/1/2020Bank of AmericaInitiated CoverageNeutral$51.00High
2/27/2020Piper SandlerBoost TargetOverweight$75.00 ➝ $80.00High
2/19/2020GuggenheimInitiated CoverageBuy$66.00High
2/18/2020BarclaysDowngradeEqual Weight ➝ Underweight$45.00Low
11/19/2019Piper Jaffray CompaniesBoost TargetOverweight$55.00 ➝ $75.00High
11/1/2019Roth CapitalBoost TargetBuy$51.00 ➝ $57.00Low
11/1/2019BarclaysDowngradeOverweight ➝ Equal Weight$37.00 ➝ $45.00High
10/15/2019BTIG ResearchSet TargetBuy$56.00High
9/13/2019BTIG ResearchSet TargetPositive ➝ Buy$56.00Medium
7/22/2019BMO Capital MarketsBoost TargetOutperform$50.00High
7/22/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$55.00High
5/8/2019BMO Capital MarketsBoost TargetOutperform$28.00 ➝ $40.00Medium
4/17/2019BTIG ResearchInitiated CoverageBuy$38.00Low
2/27/2019JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
2/22/2019BMO Capital MarketsInitiated CoverageOutperform$28.00High
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$29.00High
11/27/2018SVB LeerinkInitiated CoverageOutperform$32.00High
10/31/2018Roth CapitalInitiated CoverageBuy$28.00High
10/1/2018Bank of AmericaLower TargetNeutral ➝ Neutral$24.00 ➝ $13.00High
7/16/2018Bank of AmericaInitiated CoverageNeutral$24.00High
7/16/2018JPMorgan Chase & Co.Initiated CoverageOverweight$36.00High
7/16/2018BarclaysInitiated CoverageOverweight$32.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/7/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Eidos Therapeutics logo
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Read More

Today's Range

Now: $122.21
Low: $122.21
High: $122.21

50 Day Range

MA: $123.21
Low: $120.98
High: $128.51

52 Week Range

Now: $122.21
Low: $28.39
High: $132.54

Volume

N/A

Average Volume

128,113 shs

Market Capitalization

$4.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Eidos Therapeutics?

The following Wall Street analysts have issued research reports on Eidos Therapeutics in the last twelve months:
View the latest analyst ratings for EIDX.

What is the current price target for Eidos Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Eidos Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Eidos Therapeutics in the next year.
View the latest price targets for EIDX.

What is the current consensus analyst rating for Eidos Therapeutics?

Eidos Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EIDX.

What other companies compete with Eidos Therapeutics?

Other companies that are similar to Eidos Therapeutics include Global Blood Therapeutics, Cerevel Therapeutics, Intra-Cellular Therapies, Perrigo and Mirati Therapeutics. Learn More about companies similar to Eidos Therapeutics.

How do I contact Eidos Therapeutics' investor relations team?

Eidos Therapeutics' physical mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company's listed phone number is 415-887-1471 and its investor relations email address is [email protected] The official website for Eidos Therapeutics is www.eidostx.com. Learn More about contacing Eidos Therapeutics investor relations.